Slide 1: Full Year 2024 Results
Full Year 2024 Results Matthias Gaertner, CEO Falk Neukirch, CFO March 25, 2025
Slide 2: Executive summary, Financial overview, Guidance 2025, Appendix
1 Executive summary 2 Financial overview 3 Guidance 2025, growth story “We are creating the leading 4 Appendix European Specialty Pharma platform to treat diseases optimally with individualized medicine.” Matthias Gärtner, CEO Medios AG 2
Slide 3: Highlights FY 2024
Executive summary Highlights FY 2024 Significant increase in profitability for FY 24; in Q4 24 17.1% organic EBITDA pre growth • Revenue +5.5% to ~€1.9bn • Disproportionate EBITDA pre increase to ~€79.0m (+30.5%); significant EBITDA pre margin expansion Financials to 4.2% – strong organic growth of
Slide 4: European Compounding Platform
Executive summary European Compounding Platform • Leading position in Specialty Pharma compounding in Europe following acquisition of Ceban • 10 GMP* -(compliant) facilities • 8 GMP labs for individualized preparations in Germany and The Netherlands • 2 API1 repackaging facilities in Antwerp, Belgiu
Slide 5: QoQ – Strong EBITDA pre margins
Executive summary QoQ – Strong EBITDA pre margins in the second half of 2025 Revenue (€m) EBITDA pre¹ €m 24.6 493 483 23.2 490 431 422 441 456 451 419 393 399 399 5 17.2 16.1 15.3 15.0 15.1 14.1 14.3 14.1 14.3 11.1 4.8% EBITDA 5.0 4.8 pre1 3.6 3.6 3.6 3.5 3.3 3.5 3.3 3.6 margin 3.4 3.2 Q1 Q2 Q3 Q4 Q
Slide 6: YoY Q4 2024 – Strong disproportionate EBITDA pre growth
Executive summary YoY Q4 2024 – Strong disproportionate EBITDA pre growth Revenue in €m EBITDA pre¹ in €m 9.3% 62.8% 23.2 482.5 441.2 14.3 EBITDA pre1 4.8% margin 3.2% Q4 2023 Q4 2024 Q4 2023 Q4 2024 1 EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization.
Slide 7: YoY FY 2024: Strong EBITDA pre margin increase
Executive summary YoY FY 2024: Strong EBITDA pre margin increase Revenue in €m EBITDA pre¹ in €m 5.5% 30.5% 79.0 1,785 1,883 60.5 EBITDA pre1 4.2% margin 3.4% FY 2023 FY 2024 FY 2023 FY 2024 1 EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization. EBITDA pr
Slide 8: Group-wide ESG-management
Executive summary Group-wide ESG-management Double challenge: • First Nonfinancial Report using the European Sustainability Standards (ESRS) of the CSRD1 as reporting framework • First report after Ceban-acquisition Achievements: • KPIs were gathered to provide the basis for re- viewing, revising an
Slide 9: Financial overview
1 Executive summary 2 Financial overview 3 Guidance 2025, growth story 4 Appendix 9
Slide 10: FY 2024 – Good Group financials and strong operating CF
Financial overview FY 2024 – Good Group financials and strong operating CF In € million FY 2024 FY 2023 ∆ in % Comments Revenue 1,883.0 1,784.7 5.5% Financials including the strong contribution of Ceban (segment International Business “IB”) for seven months Gross profit1 154.6 112.0 38.0% gross marg
Slide 11: FY 2024 – Revenue growth driven by Ceban and PS contribution
Financial overview FY 2024 – Revenue growth driven by Ceban and PS contribution YoY revenue in €m FY 23 Organic Inorganic FY 24 Comments Pharmaceutical Supply (PS) 1,558.1 21.8 - 1,580.0 • Ceban acquisition led to revenue contribution of €88.8m (7 months) in IB segment Patient-Specific Therapies (PS
Slide 12: FY 2024 – EBITDA pre growth driven by strong Ceban contribution
Financial overview FY 2024 –EBITDA pre growth driven by strong Ceban contribution EBITDA pre1 in €m FY 23 Organic Inorganic FY 24 Comments Pharmaceutical Supply (PS) 46.7 3.3 - 50.0 • EBITDA pre1 of PS grew organically (€3.3m) • EBITDA pre1 of PST grew organically (€1.4m) Patient-Specific Therapies
Slide 13: FY – Strong PS & IB; turnaround of PST in 2025
Financial overview FY - Strong PS & IB (7 months); turnaround of PST in the course of 2025 Pharmaceutical Patient-specific International Internal IFRS Group Supply ‘PS‘ Therapies ‘PST’ Business ‘IB' Services consolidation YoY in € million FY 24 FY 23 FY 24 FY 23 FY 24 FY 23 FY 24 FY 23 FY 24 FY 23 F
Slide 14: Status Debt-Financing
Financial overview Status Debt-Financing • New financing structure concluded in Nov 2024 : €225m, thereof • €125m as term loan, term: 5 yrs, repayment will start in March 2025, and • €100m as Revolving credit facility (RCF), term 5 (+1 +1) yrs plus • RCF step up option of further €50m • Attractive i
Slide 15: Guidance 2025, growth story
1 Executive summary 2 Financial overview 3 Guidance 2025, growth story 4 Appendix “Medios delivers the best quality – reliably, competently and fast. These are key criteria for the optimal care of our patients.” 15
Slide 16: Disproportionate EBITDA pre increase expected
Guidance 2025 & growth story Disproportionate EBITDA pre increase expected Revenue (€bn) EBITDA pre1(€m) + 6.0% ~2.0 ~96 1.9 + 21.5% 79 Margin ~4.8 (%) 4.2 2024 2025E* 2024 2025E* 1 EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization. EBITDA pre is adjust
Slide 17: Clear strategy to build the leading European Specialty Pharma Platform
Medios at a Glance Clear strategy to build the leading European Specialty Pharma Platform Strengthening Expansion Diversification the Core Business in Europe Advanced in Germany Therapies Continue evolving out Expand compounding Become a trusted partner compounding infrastructure within Europe to ga
Slide 18: Appendix
1 Executive summary 2 Financial overview 3 Guidance 2025, growth story 4 Appendix “I work for Medios because I can contribute to patient care that meets the highest quality standards.” 18
Slide 19: Synergistic positions across the compounding value chain
Appendix Synergistic positions across the compounding value chain Compounding Services API Services Pharmacies • Tailor-made medication • Sourcing, repacking and • 23 owned pharmacies across compounded at GMP-compliant distributing APIs and excipients the Netherlands under the facilities for pharmac
Slide 20: Transformative and value enhancing acquisition
Appendix Transformative and value enhancing acquisition (As at March 2024) • First step in Medios internationalization Internationalization • Immediate market entry into three European countries: NL, BE, ES • A leading position in compounding in Northwestern Europe • First building block to establis
Slide 21: ESG highlights 2024
Executive summary ESG highlights 2024 Proportion of women 69% in workforce 0.1% Customer 47% complaint rate in management 1,208 t CO2e 64% Share of green Scope 1 & 2 electricity emissions in Germany Offset (c. -16% vs. 2023) t CO2e tonnes of CO2-equivalents | MWh Megawatt hours 21
Slide 22: Average to above-average ESG Ratings
Key Investment Highlights Average to above-average ESG Ratings 0 57 100 Exceeds the industry benchmark of 42% D– C– A+ Top 15% in the Industry CCC AAA AA Top 43% in the Industry 0 100 34 Top 50% universe ranking 100 0 39 100 Top 13% in the Industry 100 13.6 0 Top 6% in the Industry (low risk) Source
Slide 23: Q4 – Disproportionate EBITDA pre increase with great margin
Financial overview Q4 – Disproportionate EBITDA pre increase with great margin Pharmaceutical Patient-specific International Internal IFRS consolidation Group Supply ‘PS‘ Therapies ‘PST’ Business ‘IB' Services YoY in € million Q4 24 Q4 23 Q4 24 Q4 23 Q4 24 Q4 23 Q4 24 Q4 23 Q4 24 Q4 23 Q4 24 Q4 23 T
Slide 24: Q4 2024: Reflects focus on high-margin revenue
Financial overview Q4 2024: Reflects focus on high-margin revenue YoY Revenue in €m Q4 23 Organic Inorganic Q4 24 Comments Pharmaceutical Supply (PS) 390.1 -1.4 - 388.8 • Inorganic growth driven by Ceban acquisition Patient-Specific Therapies (PST) 51.0 1.1 - 52.1 International Business (IB) n/a - 4
Slide 25: Q4 2024 – Disproportionate EBITDA pre growth
Financial overview Q4 2024 – Disproportionate EBITDA pre growth YoY EBITDA pre1 in €m Q4 23 Organic Inorganic Q4 24 Comments Pharmaceutical Supply (PS) 13.0 0.0 - 13.0 • Successful integration of Ceban led to EBITDA pre1 contribution of €6.5m Patient-Specific Therapies (PST) 4.0 2.5 - 6.5 Internatio
Slide 26: Key figures (1/2)
Appendix Key figures (1/2) in € thousand FY 2024 FY 2023 ∆ in % Q4 2024 Q4 2023 ∆ in % Revenue 1,883,038 1,784,703 5.5% 482,533 441,245 9.4% Pharmaceutical Supply 1,579,989 1,558,148 1.4% 388,765 390,143 -0.3% Patient-Specific Therapies 213,642 225,964 -5.4% 52,068 51,003 2.1% International Business
Slide 27: Key figures (2/2)
Appendix Key figures (2/2) in € thousand FY 2024 FY 2023 ∆ in % Q4 2024 Q4 2023 ∆ in % Earnings per share (in €) Undiluted 0.51 0.79 -35.8% 0.08 0.10 -20.0% Diluted 0.51 0.79 -35.8% 0.08 0.10 -20.0% Investments (CAPEX) 6,308 1,262 >100% 2,752 401 >100% Cash flow from operating activities 73,663 16,4
Slide 28: Contact
Contact Claudia Nickolaus Head of Investor & Public Relations, ESG Communications Phone +49 30 232 566 800 claudia.nickolaus@medios.group
Slide 29: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of contained herein are as up to date as is reasonably possible and are subject to revision in the the C
Slide 30: Full Year 2024 Results
Full Year 2024 Results Matthias Gaertner, CEO Falk Neukirch, CFO March 25, 2025